Full Event Guide

Talks from 19+ industry leaders who are pioneering peptide drug conjugates, oligonucleotide drug conjugates, fragment drug conjugates, bispecific drug conjugates, degrader conjugates, radio conjugates, and more.  

Discussion-based workshops covering the challenges that accompany developing first-in-class conjugates and the linker chemistry considerations when working with novel payloads.

6 hours of dedicated networking time to build strong relationships with industry leaders, researchers, and potential investors to overcome challenges and accelerate development of novel conjugate drugs. 

A panel discussion to gain first hand insights from successful biotech companies and experienced investors on navigating the funding landscape, understand investor expectations, and effectively present projects to secure funding. 

Screenshot 2024-07-22 110643
49772 - Speaker Banners (3)
49772 - Speaker Banners (4)
49772 - Speaker Banners (6)